Longevity Science: Research Landscape and Resource Allocation
Listen to episode
About this episode
Biotech investment in aging biology is accelerating — what does the current evidence base look like, and how does longevity research sit alongside other medical research priorities? A wave of biotech startups, celebrity investors, and research institutions are directing billions toward the hypothesis that aging can be slowed, reversed, or treated as a disease. Recent trials involving senolytics, rapamycin, and GLP-1 adjacents have produced notable data, alongside a media ecosystem with a tendency toward strong claims. The distance between peer-reviewed geroscience and the supplement-oriented longevity influencer space has become a point of debate in the field. — Independent bias measurement: lean -3.5 (−10..+10) · epistemic quality 7.7/10 · scored by 3 external AI judges (DeepSeek, Cohere, Llama). Methodology: https://hellohumans.ai/methodology
More AI podcast episodes
Browse all →Want to find AI jobs?
Join thousands of AI professionals finding their next opportunity